Anti-IL22RA ADCC Enhanced Antibody (ARGX-112) is an ADCC enhanced antibody produced by our Afuco™ platform. ARGX-112 is a novel, fully human antibody neutralizing both IL20 and IL22 signaling through blockade of their common receptor, IL22R, with low picomolar potency. IL20 and IL22 are involved in proliferation and differentiation of keratinocytes (skin cells) and when over-expressed, are implicated in autoimmune diseases of the skin, including atopic dermatitis, psoriasis and pustular psoriasis. ARGX-112 has been shown to be highly effective in several preclinical models of chronic skin inflammation.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-563 | Recombinant Anti-IL-22RA Antibody | ELISA, WB, Dot, FuncS | IgG |
MHH-563 | Recombinant Human Anti-IL-22RA Antibody | WB, IP, FuncS | IgG |
There are currently no Customer reviews or questions for AFC-401CL. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.